SlideShare a Scribd company logo

C gmp final

Download as PPTX, PDF
M
Mujeeb Shaikh

cGMP as per shedule M outlines the Good Manufacturing Practices that must be followed for pharmaceutical manufacturing according to the Drugs and Cosmetics Act of India. It covers requirements for facilities, equipment, personnel, sanitation, documentation, quality control, packaging and labeling. All aspects of production from raw materials to finished products must meet GMP standards to ensure consistency and quality of manufactured drugs. Detailed written procedures and records are required for all manufacturing processes.

Science
1 of 38
Download to read offline
1
2
3
4
5
6
7
8
Most read
9
Most read
10
11
12
13
14
15
16
Most read
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
cGMP as per shedule M PRESENTED BY :Mujeeb Shaikh (Ms) M.PHARM(P.Q.A). Allana College of Pharmacy DEPARTMENT OF pharmaceutical QUALITY ASSURANCE
What is GMP ?: What is GMP ? GMP is that part of Quality assurance which ensures that the products are consistently manufactured and controlled to the Quality standards appropriate to their intended use. "GMP" - A set of principles and procedures which, when followed by manufacturers for therapeutic goods, helps ensure that the products manufactured will have the required quality. What is cGMP ?: What is cGMP ? Usually see “cGMP” – where c = current, to emphasize that the expectations are dynamic .
What Is Covered in GMPs?: GMPs Organization & Personnel Buildings & Facilities Equipment Control of Components, Containers & Closures Production & Process Control Holding & Distribution Laboratory Controls Records & Reports Returned & Salvaged Products
GMP Covers…:  All aspects of production; from the starting materials, premises and equipment to the training and personal hygiene of staff .  Detailed, written procedures are essential for each process that could affect the quality of the finished product.  There must be systems to provide documented proof that correct procedures are consistently followed at each step in the manufacturing process - every time a product is made
 DRUG AND COSMETIC ACT IN INDIA  In 1937 a Bill was introduced in the Central Legislative Assembly to give effect to the recommendations of the Drugs Enquiry Committee to regulate the import of drugs into British India.  Provincial Governments got the resolution passed from the Provincial Legislatures and sent them to the Central Government for getting through the Bill to regulate the import, manufacture, distribution and sale of Drugs and Cosmetics. There upon the Drugs and Cosmetics Bill was introduced in the Central Legislative Assembly.
GENERAL REQUIREMENTS DRUG AND COSMETIC ACT 1940 SCHEDULE M
1.1 . Location and surroundings . The factory building(s) for manufacture of drugs shall be so situated that it avoid risk of contamination from external environmental including open sewage, drain, public lavatory Building and premises . They shall conform to the conditions laid down in the Factories Act, 1948 (63 of 1948) The premises used for manufacturing, processing, warehousing, packaging labelling and testing purposes shall be . ( i ) compatible with other drug manufacturing operations (ii) adequately working space to avoid the risk of mix-up between different (b) avoid the possibilities of contamination and cross contamination (iii) designed / constructed / maintained to prevent entry of insects, pests, birds, and rodents. (iv) well lighted, effectively ventilated, with proper Air Handling Units.
C gmp final
1.3 Water System There shall be validated system for treatment of water in accordance with standards specified by the Bureau of Indian Standards or Local Municipality or Pharmacopoeial specification. Water shall be stored in tanks, which do not adversely affect quality of water and ensure freedom from and records maintained by the licensee in this behalf. microbiological growth. The tank shall be cleaned periodically and records maintained by the licensee in this behalf
1.4. Disposal of waste . ( i ) The disposal of sewage and effluents (solid, liquid and gas) be in conformity with the requirements of Environment Pollution Control Board. (ii) All bio-medical waste shall be destroyed as per the provisions of the Bio-Medical Waste (Management and Handling) Rules, 1996. (iii) Records shall be maintained for all disposal of waste. (iv) Provisions shall be made for the proper and safe storage of waste materials awaiting disposal.
C gmp final
2. Warehousing Area . 2.1 Adequate areas to allow orderly warehousing of various categories of materials. 2.2 Good storage conditions 2.3 There shall be a separate sampling area in the warehousing area for active raw materials and excipients. 2.4. Segregation shall be provided for the storage of rejected, recalled or returned materials or products. 2.5 Highly hazardous, poisonous and explosive materials shall be stored in safe and secure areas
3. Production area 3.1. Separate dedicated and self-contained facilities shall be made available for the production of sensitive pharmaceutical products. 3.2. Orderly and logical positioning of equipment and materials and movement of personnel and to minimize risk of omission or wrong application of any manufacturing and control measures. 3.3. Services lines shall preferably be identified by colours and the nature of the supply and direction of the flow shall be marked/indicated.
4. Ancillary Areas: 4. Ancillary Areas 4.1 Rest and refreshment rooms shall be separate from other areas. Facilities for changing, storing clothes and for washing and toilet purposes shall be adequate for the number of users. 4.2 Animal houses shall be those as prescribed in Rule 150-C(3) of the Drugs and Cosmetics Rules, 1945 which shall be adopted for production purposes.
5. Quality Control Area. 5.1. QC Lab. shall be independent of the production areas. Separate areas each for physico-chemical, biological, microbiological or radio-isotope analysis. 5.2 Adequate space shall be provided to avoid mix-ups and proper storage for test samples, retained samples, reference standards, reagents and records.
6. Personnel . 6.1. Qualifications and practical experience in the relevant field. 6.2. Written duties of technical and Quality Control personnel shall be laid and following strictly. 6.3. Number of personnel employed shall be adequate and in direct proportion to the workload.
7. Health, clothing and sanitation of workers . 7.1 Prior to employment, all personnel, shall undergo medical examination and a periodically examination is carried out, records are also maintained. 7.2 Proper training shall be given to all employees to maintain personnel hygiene and adequate facilities for personal cleanliness. 7.3 Smoking, eating, drinking, chewing , food, drink and personal medicines not permitted in production, laboratory, storage area.
8. Manufacturing Operations and Controls. 8.1 All manufacturing operations shall be carried out under the supervision of technical staff approved by the Licensing Authority
8.2. Precautions against mix-up and cross- contamination- 8.2.1. By proper air handling system, pressure differential, segregation, status labelling and cleaning. Proper records and SOP there of shall be maintained. 8.2.2 Processing of sensitive drugs and cytotoxic substances in segregated areas. 8.2.3 Proper labelling of materials and equipments. 8.2.4 Packaging lines shall be independent and adequately segregated. 8.2.5 All printing and overprinting shall be authorized in writing. 8.2.6 The manufacturing environment maintained at the required levels of temperature, humidity and cleanliness.
9. Sanitation in the Manufacturing Premises. 9.1 The manufacturing premises shall be cleaned and in an orderly manner. 9.2 The manufacturing areas shall not be used for other operations. 9.3 A routine sanitation program shall be drawn up which shall be properly recorded and which indicate– (a)specific areas to be cleaned and cleaning intervals; (b)cleaning procedure to be followed (c)personnel assigned to and responsible for the cleaning operation.
10. Raw Materials. 10.1 Keeping an inventory of all raw materials to be used and maintain records as per Schedule U. 10.2 Authorized staff who examine each consignment for its integrity. 10.3 Labelling with the following information: (a) name of the product and the internal code reference and analytical reference number; (b) manufacturer’s name, address and batch number; (c) the status of the contents (e.g. quarantine, under test, released, approved, rejected); and (d) the manufacturing date, expiry date and re-test date.
11. Equipment. 11.1 Equipment shall be located, designed, constructed, adapted to suit the operations and logbook is maintained. 11.2 Equipment shall be calibrated and checked on a scheduled basis in accordance to SOP and maintain records. 11.3 Equipment shall be inert and defective are removed and labelled .
12. Documentation and Records. Documentation is an essential part of the Quality assurance system and Its aim is to define the specifications for all materials, method of manufacture and control to release a batch of drug for sale. 12.1 Documents shall be approved, signed and dated by authorized persons. 12.2 Documents shall specify : the title, nature and purpose laid out in an orderly fashion kept up to date. 12.3 SOP shall be retained for at least one year after the expiry date of the finished product. 12.4 Data may be recorded by electronic data processing systems but Master Formulae and detailed operating procedures relating to the system in use shall also be available in a hard copy to facilitate checking of the accuracy of the records .
13. Labels and other Printed Materials . Labels are necessary for identification of the drugs and their use. The Printing shall be done in bright colours and in a legible manner. The label shall carry all the prescribed details about the product. 13.1 All containers and equipment shall bear appropriate labels. 13.2 Prior to release, all labels for containers shall be examined by the QC Department. 13.3 Records of receipt of all labelling and packaging materials shall be maintained and unused coded and damaged labels and packaging materials shall be destroyed and recorded.
14. Quality Assurance. It is a wide-ranging concept concerning all matters that individually or collectively influence the quality of a product. It shall ensure that: - (a) the pharmaceutical products are designed and developed in a way that takes account of the requirement of GMP ,GLP and GCP. (b) adequate controls on starting materials, intermediate products, and other in-process controls, calibrations, and validations are carried out. (c) products are released after authorized persons have certified.
15. Self inspection and Quality Audit: 15. Self inspection and Quality Audit It is for the assessment of all or part of a system with the specific purpose of improving it. 15.1 The program is designed to detect shortcomings in the implementation of GMP and to recommend the necessary corrective actions. Self-inspections shall be performed routinely and on specific ocasions . The team responsible for self-inspection shall consist of independent, experienced, qualified persons from within or outside the company who can evaluate the implementation of GMP objectively; all recommendations for corrective action shall be implemented. 15.2 The procedure for self-inspection shall be documented indicating self-inspection results; evaluation, conclusions and recommended corrective actions with
16. Quality Control System. Quality control shall be concerned with sampling, specifications, testing, documentation, release procedures . Materials are not released for use, nor products released for sale or supply until their quality has been judged to be satisfactory. 16.1 QC lab should have qualified and experience staff. 16.2 QC lab. may be divided into Chemical, Instrumentation, Microbiological and Biological testing. 16.3 The QC department shall conduct stability studies of the products to ensure and assign their shell life . All records of such studies shall be maintained. 16.4 All instruments shall be calibrated and validated before adopted for routine testing. 16.5 Pharmacopoeia, reference standards, working standards, references spectra, other reference materials and technical books, as required, shall be available in the
17. Specification 17.1 For raw materials and packaging materials. They shall include : a) the designated name and internal code reference; b) reference, if any, to a pharmacopoeial monograph; c) qualitative and quantitative requirements with acceptance limits; d) name and address of manufacturer or supplier and original manufacturer of the material; e) specimen of printed material; f) directions for sampling and testing or reference to procedures ; g) storage conditions; and h) maximum period of storage before re-testing. 17.2 For finished products. Appropriate specifications for finished products shall include: - a) the designated name of the product and the code reference; b) the formula or
18. Master Formula Records . There shall be Master Formula records relating to all manufacturing procedures for each product and batch size. These shall be prepared and endorsed by head of production and quality control. The master Formula shall include : - (a) the name of the product together with product reference code relating to its specifications; (b) the patent or proprietary name of the product along with the generic name, a description of the dosage form, strength, composition of the product and batch size; (c) name, quantity, and reference number of all the starting materials to be used. (d) A statement of the processing location and the principal equipment to be used. (e) detailed stepwise processing instructions and the time taken for each step; (f) the instructions for in-process control with their limits;
19. Packing Records . There shall be authorised packaging instructions for each product, pack size and type . These shall include or have a reference to the following: - (a) name of the product; (b) description of the dosage form, strength and composition; (c) the pack size expressed in terms of the number of doses, weight or volume of the product in the final container; (d) special precautions to be observed, including a careful examination of the area and equipment in order to ascertain the line clearance before the operations begin.
20. Batch Packaging Records . A batch packaging record shall be kept for each batch or part batch processed. It shall be based on the relevant parts of the packaging instructions, and the method of preparation of such records shall be designed to avoid transcription errors. 21. Batch Processing Records. There shall be Batch Processing Record for each product. It shall be based on the relevant parts of the currently approved Master Formula. The method of preparation of such records included in the Master Formula shall be designed to avoid transcription errors.
22. Standard Operating Procedures (SOPs) There shall be written SOP and records for the : receipt of each delivery of raw, primary and printed material. internal labelling, quarantine and storage of starting materials, packaging materials and other materials, as appropriate. for each instrument and equipment. sampling which include the person(s) authorized to take the samples. describing the details of the batch numbering which ensure that each batch of intermediate, bulk or finished product is identified with a specific batch number. testing materials and products at different stages of manufacture, describing the methods and equipment to be used.
23. Reference Samples 23.1 Each lot of every active ingredient, in a quality sufficient to carryout all the tests, except sterility and pyrogens / Bacterial Endotoxin Test, shall be retained for a period of 3 months after the date of expiry of the last batch produced from that active ingredient. 23.2. Samples of finished formulations shall be stored in the same or simulated containers in which the drug has been actually marketed.
24.1 Reprocessing and Recoveries 2. Validation and process validation. Validation studies shall be an essential part of GMP and shall be conducted as per the pre-defined protocols. A written report summarizing recorded results and conclusions shall be prepared, documented and maintained. When any new Master Formula or method of preparation is adopted, steps shall be taken to demonstrate its suitability for routine processing. Significant changes to the manufacturing process, including any changes in equipment or materials shall be validated.
24. Complaints and Adverse Reactions. All complaints there of concerning product quality shall be carefully reviewed and recorded according to written procedures. Each complaint shall be investigated /evaluated by the designated personnel of the company and records of investigation and remedial action taken thereof shall be maintained. Reports of serious adverse drug reactions resulting from the use of a drug shall be forthwith reported to the concerned licensing authority.
25. Site Master File. The licensee shall prepare a succinct document in the form of Site Master File containing specific and factual GMP about the production and/or control of pharmaceutical manufacturing preparations carried out at the licensed premises. It shall contain the following: - General information, Personnel. Premises. Equipment. Sanitation. Documentation. Production. Quality Control. Loan licence manufacture and licensee. Distribution, complaints and product recall. Export of drugs.
References: http://www.medindia.net/indian_health_act/drugs-and- cosmetics-act-1940-introduction.htm www.vakilno1.com/bareacts/drugsandcosmeticsact/drug sandcosmeticsact.htm http://www.dancewithshadows.com/pillscribe/cgmp- regulations-in-india-to-be-diluted/ http://www.prescriptiondrug-info.com/topics/drug-and- cosmetic-act/
Thank you!!!!

More Related Content

PPTX
Packaging material vendor audit
RavichandraNadagouda
 
PPTX
Quality by design (QbD) and process analytical technology (PAT)
shreyashChaudhari6
 
PPTX
Auditing in Solid Oral Dosage Form Production Department
SANJAY KUMAR PUROHIT
 
PPTX
Validation utility system
PRANJAY PATIL
 
PPTX
Role of quality systems and audits in pharmaceutical manufacturing environment
Malay Pandya
 
PPTX
Auditing of quality assurance and maintenance of engineering department
Priyanka Kandhare
 
PPTX
Vendor Audit
PRAVADA
 
PPTX
Qualification of Autoclave.pptx
Dhruvi50
 
Packaging material vendor audit
RavichandraNadagouda
 
Quality by design (QbD) and process analytical technology (PAT)
shreyashChaudhari6
 
Auditing in Solid Oral Dosage Form Production Department
SANJAY KUMAR PUROHIT
 
Validation utility system
PRANJAY PATIL
 
Role of quality systems and audits in pharmaceutical manufacturing environment
Malay Pandya
 
Auditing of quality assurance and maintenance of engineering department
Priyanka Kandhare
 
Vendor Audit
PRAVADA
 
Qualification of Autoclave.pptx
Dhruvi50
 

What's hot (20)

PPTX
Auditing of capsule, sterile production and packaging
MittalRohit2
 
PPTX
Vendor qualification
KhushbooKunkulol
 
PPTX
Quality maintenance
ANKUSH JADHAV
 
DOCX
Auditing of vendors and production department
PRANJAY PATIL
 
PPTX
Qualification of tablet compression (machine) & Capsule filling machine
Yash Menghani
 
PPTX
Pharmaceutical inspection convention
RAGHAV DOGRA
 
PPTX
Manufacturing operation and controls
sachin pawar
 
PPTX
Management of over-Exposure to chemicals and TLV concept
SwarajLohar
 
PPTX
cGMP Guidelines According to Schedule M
ANKUSH JADHAV
 
PPT
Process validation Ointment Cream LIquid Oral
UIOP, Pt. Ravi Shankar shukla University
 
PPTX
Equipment Qualification
Priyanka Kandhare
 
PDF
Building of Raw Material.pdf
Dr. Dinesh Mehta
 
PPTX
Pat process analytical technique
SalmanLatif14
 
PPTX
Validation of hvac
Raghavendra institute of pharmaceutical education and research .
 
PPTX
Quality assurance maintenance of hvac system in pharmaceutical industry
ShahbazNadaf
 
PDF
CHAPTER-1 Information Gathering and Administration.pdf
Dr. Dinesh Mehta
 
PPTX
Self inspection
Bangaluru
 
PPTX
Critical Hazard Management System (CHMS)
AnkitVasoya5
 
PPTX
Supplemental new drug application
garimasaini33
 
PPTX
Manufacturing Operations and Controls
Sayali Powar
 
Auditing of capsule, sterile production and packaging
MittalRohit2
 
Vendor qualification
KhushbooKunkulol
 
Quality maintenance
ANKUSH JADHAV
 
Auditing of vendors and production department
PRANJAY PATIL
 
Qualification of tablet compression (machine) & Capsule filling machine
Yash Menghani
 
Pharmaceutical inspection convention
RAGHAV DOGRA
 
Manufacturing operation and controls
sachin pawar
 
Management of over-Exposure to chemicals and TLV concept
SwarajLohar
 
cGMP Guidelines According to Schedule M
ANKUSH JADHAV
 
Process validation Ointment Cream LIquid Oral
UIOP, Pt. Ravi Shankar shukla University
 
Equipment Qualification
Priyanka Kandhare
 
Building of Raw Material.pdf
Dr. Dinesh Mehta
 
Pat process analytical technique
SalmanLatif14
 
Validation of hvac
Raghavendra institute of pharmaceutical education and research .
 
Quality assurance maintenance of hvac system in pharmaceutical industry
ShahbazNadaf
 
CHAPTER-1 Information Gathering and Administration.pdf
Dr. Dinesh Mehta
 
Self inspection
Bangaluru
 
Critical Hazard Management System (CHMS)
AnkitVasoya5
 
Supplemental new drug application
garimasaini33
 
Manufacturing Operations and Controls
Sayali Powar
 
Ad

Similar to C gmp final (20)

PPTX
Good manufacturing practices- schedule
jijothomaschirayil
 
PDF
DRUGS AND COSMETICS ACT 1940 AND RULES THEIR UNDER 1945 SCHEDULE M.
TUSHAR MORANKAR
 
PPTX
SCHEDULE M,industrial pharmacy 3rd sem.pptx
naikanu3813
 
PPTX
SCHEDULE M, Pharmaceutical Jurisprudence, 5th sem
naikanu3813
 
PDF
1.c gmp as per schedule m
srikrupa institute of pharmaceutical analysis
 
PDF
Gmp
Reshma Fathima .K
 
PPTX
Schedule m
Rajkumar Kumawat
 
PPTX
GMP, Goods manufacturer Practices, Drug and Cosmetic act
DrSampuranSuahg
 
PPTX
C gmp
PRANJAY PATIL
 
PPTX
GMP.pptx
laxmidharsahoo7
 
PPT
Schedule M drugs and Cosmetics_Good manufacturing practices
VETERINARY COLLEGE AND RESEARCH INSTITUTE, ORATHANADU - TANUVAS
 
PPTX
GMP
Rungta college of Pharmaceutical science
 
PDF
Schedule M Drugs and Cosmetics Act, 1940 & Rules pharmaceutical jurisprudence
IqraSaifi19
 
PPT
Gmp
Navneeth Krishna
 
PPTX
PHARMACEUTICAL PRODUCTION MANAGEMENT & INVENTORY CONTROL
Arunpandiyan59
 
PPTX
CGMP
SALMA RASHID SHAIKH
 
PPTX
pratik ghive cGMP According to schedule M
pratikghive82
 
PPTX
C gmp
SACHIN C P
 
PPTX
GMP presentation.pptx
garima mailk
 
PPTX
Mph 02 (shubham)
Drx Shubham Badhe
 
Good manufacturing practices- schedule
jijothomaschirayil
 
DRUGS AND COSMETICS ACT 1940 AND RULES THEIR UNDER 1945 SCHEDULE M.
TUSHAR MORANKAR
 
SCHEDULE M,industrial pharmacy 3rd sem.pptx
naikanu3813
 
SCHEDULE M, Pharmaceutical Jurisprudence, 5th sem
naikanu3813
 
1.c gmp as per schedule m
srikrupa institute of pharmaceutical analysis
 
Gmp
Reshma Fathima .K
 
Schedule m
Rajkumar Kumawat
 
GMP, Goods manufacturer Practices, Drug and Cosmetic act
DrSampuranSuahg
 
C gmp
PRANJAY PATIL
 
GMP.pptx
laxmidharsahoo7
 
Schedule M drugs and Cosmetics_Good manufacturing practices
VETERINARY COLLEGE AND RESEARCH INSTITUTE, ORATHANADU - TANUVAS
 
GMP
Rungta college of Pharmaceutical science
 
Schedule M Drugs and Cosmetics Act, 1940 & Rules pharmaceutical jurisprudence
IqraSaifi19
 
Gmp
Navneeth Krishna
 
PHARMACEUTICAL PRODUCTION MANAGEMENT & INVENTORY CONTROL
Arunpandiyan59
 
CGMP
SALMA RASHID SHAIKH
 
pratik ghive cGMP According to schedule M
pratikghive82
 
C gmp
SACHIN C P
 
GMP presentation.pptx
garima mailk
 
Mph 02 (shubham)
Drx Shubham Badhe
 
Ad

Recently uploaded (20)

PPTX
microscope-Lecturecjchchchchcuvuvhc.pptx
jaylaurencenobleza
 
PDF
Crime Scene Investigation: A Guide for Law Enforcement (2013 Update)
alexayranikudy
 
PPTX
EPIDURAL ANESTHESIA ANATOMY AND PHYSIOLOGY.pptx
PrabakaranMP1
 
PPT
POSITIONING IN OPERATION THEATRE ROOM.ppt
PrabakaranMP1
 
PPT
protein biochemistry.ppt for university classes
bayewodajo27
 
PDF
IFIT3 RNA-binding activity primores influenza A viruz infection and translati...
saracelre
 
PPTX
Vitamins & Minerals: Complete Guide to Functions, Food Sources, Deficiency Si...
Muhammad Sajid Afridi
 
PPTX
Protein & Amino Acid Structures Levels of protein structure (primary, seconda...
Muhammad Sajid Afridi
 
PPTX
Production technology of seed spices,,,,
Jyothi Hosamath
 
PPTX
famous lake in india and its disturibution and importance
judesebina
 
PPTX
DRUG THERAPY FOR SHOCK gjjjgfhhhhh.pptx.
vipvivek704
 
PDF
VARICELLA VACCINATION: A POTENTIAL STRATEGY FOR PREVENTING MULTIPLE SCLEROSIS
ijab2
 
PPTX
1.pptx 2.pptx for biology endocrine system hum ppt
Dhananjaysankhla
 
PPTX
Introduction to Fisheries Biotechnology_Lesson 1.pptx
Esther Pongcol
 
PDF
MIRIDeepImagingSurvey(MIDIS)oftheHubbleUltraDeepField
Sérgio Sacani
 
PPTX
7. General Toxicologyfor clinical phrmacy.pptx
faysalphr
 
PDF
Biophysics 2.pdffffffffffffffffffffffffff
MiraMusleh
 
DOCX
Viruses (History, structure and composition, classification, Bacteriophage Re...
Educator
 
PPTX
ANEMIA WITH LEUKOPENIA MDS 07_25.pptx htggtftgt fredrctvg
vedvyas5668
 
PDF
bbec55_b34400a7914c42429908233dbd381773.pdf
agambirev
 
microscope-Lecturecjchchchchcuvuvhc.pptx
jaylaurencenobleza
 
Crime Scene Investigation: A Guide for Law Enforcement (2013 Update)
alexayranikudy
 
EPIDURAL ANESTHESIA ANATOMY AND PHYSIOLOGY.pptx
PrabakaranMP1
 
POSITIONING IN OPERATION THEATRE ROOM.ppt
PrabakaranMP1
 
protein biochemistry.ppt for university classes
bayewodajo27
 
IFIT3 RNA-binding activity primores influenza A viruz infection and translati...
saracelre
 
Vitamins & Minerals: Complete Guide to Functions, Food Sources, Deficiency Si...
Muhammad Sajid Afridi
 
Protein & Amino Acid Structures Levels of protein structure (primary, seconda...
Muhammad Sajid Afridi
 
Production technology of seed spices,,,,
Jyothi Hosamath
 
famous lake in india and its disturibution and importance
judesebina
 
DRUG THERAPY FOR SHOCK gjjjgfhhhhh.pptx.
vipvivek704
 
VARICELLA VACCINATION: A POTENTIAL STRATEGY FOR PREVENTING MULTIPLE SCLEROSIS
ijab2
 
1.pptx 2.pptx for biology endocrine system hum ppt
Dhananjaysankhla
 
Introduction to Fisheries Biotechnology_Lesson 1.pptx
Esther Pongcol
 
MIRIDeepImagingSurvey(MIDIS)oftheHubbleUltraDeepField
Sérgio Sacani
 
7. General Toxicologyfor clinical phrmacy.pptx
faysalphr
 
Biophysics 2.pdffffffffffffffffffffffffff
MiraMusleh
 
Viruses (History, structure and composition, classification, Bacteriophage Re...
Educator
 
ANEMIA WITH LEUKOPENIA MDS 07_25.pptx htggtftgt fredrctvg
vedvyas5668
 
bbec55_b34400a7914c42429908233dbd381773.pdf
agambirev
 

C gmp final

  • 1. cGMP as per shedule M PRESENTED BY :Mujeeb Shaikh (Ms) M.PHARM(P.Q.A). Allana College of Pharmacy DEPARTMENT OF pharmaceutical QUALITY ASSURANCE
  • 2. What is GMP ?: What is GMP ? GMP is that part of Quality assurance which ensures that the products are consistently manufactured and controlled to the Quality standards appropriate to their intended use. "GMP" - A set of principles and procedures which, when followed by manufacturers for therapeutic goods, helps ensure that the products manufactured will have the required quality. What is cGMP ?: What is cGMP ? Usually see “cGMP” – where c = current, to emphasize that the expectations are dynamic .
  • 3. What Is Covered in GMPs?: GMPs Organization & Personnel Buildings & Facilities Equipment Control of Components, Containers & Closures Production & Process Control Holding & Distribution Laboratory Controls Records & Reports Returned & Salvaged Products
  • 4. GMP Covers…:  All aspects of production; from the starting materials, premises and equipment to the training and personal hygiene of staff .  Detailed, written procedures are essential for each process that could affect the quality of the finished product.  There must be systems to provide documented proof that correct procedures are consistently followed at each step in the manufacturing process - every time a product is made
  • 5.  DRUG AND COSMETIC ACT IN INDIA  In 1937 a Bill was introduced in the Central Legislative Assembly to give effect to the recommendations of the Drugs Enquiry Committee to regulate the import of drugs into British India.  Provincial Governments got the resolution passed from the Provincial Legislatures and sent them to the Central Government for getting through the Bill to regulate the import, manufacture, distribution and sale of Drugs and Cosmetics. There upon the Drugs and Cosmetics Bill was introduced in the Central Legislative Assembly.
  • 6. GENERAL REQUIREMENTS DRUG AND COSMETIC ACT 1940 SCHEDULE M
  • 7. 1.1 . Location and surroundings . The factory building(s) for manufacture of drugs shall be so situated that it avoid risk of contamination from external environmental including open sewage, drain, public lavatory Building and premises . They shall conform to the conditions laid down in the Factories Act, 1948 (63 of 1948) The premises used for manufacturing, processing, warehousing, packaging labelling and testing purposes shall be . ( i ) compatible with other drug manufacturing operations (ii) adequately working space to avoid the risk of mix-up between different (b) avoid the possibilities of contamination and cross contamination (iii) designed / constructed / maintained to prevent entry of insects, pests, birds, and rodents. (iv) well lighted, effectively ventilated, with proper Air Handling Units.
  • 9. 1.3 Water System There shall be validated system for treatment of water in accordance with standards specified by the Bureau of Indian Standards or Local Municipality or Pharmacopoeial specification. Water shall be stored in tanks, which do not adversely affect quality of water and ensure freedom from and records maintained by the licensee in this behalf. microbiological growth. The tank shall be cleaned periodically and records maintained by the licensee in this behalf
  • 10. 1.4. Disposal of waste . ( i ) The disposal of sewage and effluents (solid, liquid and gas) be in conformity with the requirements of Environment Pollution Control Board. (ii) All bio-medical waste shall be destroyed as per the provisions of the Bio-Medical Waste (Management and Handling) Rules, 1996. (iii) Records shall be maintained for all disposal of waste. (iv) Provisions shall be made for the proper and safe storage of waste materials awaiting disposal.
  • 12. 2. Warehousing Area . 2.1 Adequate areas to allow orderly warehousing of various categories of materials. 2.2 Good storage conditions 2.3 There shall be a separate sampling area in the warehousing area for active raw materials and excipients. 2.4. Segregation shall be provided for the storage of rejected, recalled or returned materials or products. 2.5 Highly hazardous, poisonous and explosive materials shall be stored in safe and secure areas
  • 13. 3. Production area 3.1. Separate dedicated and self-contained facilities shall be made available for the production of sensitive pharmaceutical products. 3.2. Orderly and logical positioning of equipment and materials and movement of personnel and to minimize risk of omission or wrong application of any manufacturing and control measures. 3.3. Services lines shall preferably be identified by colours and the nature of the supply and direction of the flow shall be marked/indicated.
  • 14. 4. Ancillary Areas: 4. Ancillary Areas 4.1 Rest and refreshment rooms shall be separate from other areas. Facilities for changing, storing clothes and for washing and toilet purposes shall be adequate for the number of users. 4.2 Animal houses shall be those as prescribed in Rule 150-C(3) of the Drugs and Cosmetics Rules, 1945 which shall be adopted for production purposes.
  • 15. 5. Quality Control Area. 5.1. QC Lab. shall be independent of the production areas. Separate areas each for physico-chemical, biological, microbiological or radio-isotope analysis. 5.2 Adequate space shall be provided to avoid mix-ups and proper storage for test samples, retained samples, reference standards, reagents and records.
  • 16. 6. Personnel . 6.1. Qualifications and practical experience in the relevant field. 6.2. Written duties of technical and Quality Control personnel shall be laid and following strictly. 6.3. Number of personnel employed shall be adequate and in direct proportion to the workload.
  • 17. 7. Health, clothing and sanitation of workers . 7.1 Prior to employment, all personnel, shall undergo medical examination and a periodically examination is carried out, records are also maintained. 7.2 Proper training shall be given to all employees to maintain personnel hygiene and adequate facilities for personal cleanliness. 7.3 Smoking, eating, drinking, chewing , food, drink and personal medicines not permitted in production, laboratory, storage area.
  • 18. 8. Manufacturing Operations and Controls. 8.1 All manufacturing operations shall be carried out under the supervision of technical staff approved by the Licensing Authority
  • 19. 8.2. Precautions against mix-up and cross- contamination- 8.2.1. By proper air handling system, pressure differential, segregation, status labelling and cleaning. Proper records and SOP there of shall be maintained. 8.2.2 Processing of sensitive drugs and cytotoxic substances in segregated areas. 8.2.3 Proper labelling of materials and equipments. 8.2.4 Packaging lines shall be independent and adequately segregated. 8.2.5 All printing and overprinting shall be authorized in writing. 8.2.6 The manufacturing environment maintained at the required levels of temperature, humidity and cleanliness.
  • 20. 9. Sanitation in the Manufacturing Premises. 9.1 The manufacturing premises shall be cleaned and in an orderly manner. 9.2 The manufacturing areas shall not be used for other operations. 9.3 A routine sanitation program shall be drawn up which shall be properly recorded and which indicate– (a)specific areas to be cleaned and cleaning intervals; (b)cleaning procedure to be followed (c)personnel assigned to and responsible for the cleaning operation.
  • 21. 10. Raw Materials. 10.1 Keeping an inventory of all raw materials to be used and maintain records as per Schedule U. 10.2 Authorized staff who examine each consignment for its integrity. 10.3 Labelling with the following information: (a) name of the product and the internal code reference and analytical reference number; (b) manufacturer’s name, address and batch number; (c) the status of the contents (e.g. quarantine, under test, released, approved, rejected); and (d) the manufacturing date, expiry date and re-test date.
  • 22. 11. Equipment. 11.1 Equipment shall be located, designed, constructed, adapted to suit the operations and logbook is maintained. 11.2 Equipment shall be calibrated and checked on a scheduled basis in accordance to SOP and maintain records. 11.3 Equipment shall be inert and defective are removed and labelled .
  • 23. 12. Documentation and Records. Documentation is an essential part of the Quality assurance system and Its aim is to define the specifications for all materials, method of manufacture and control to release a batch of drug for sale. 12.1 Documents shall be approved, signed and dated by authorized persons. 12.2 Documents shall specify : the title, nature and purpose laid out in an orderly fashion kept up to date. 12.3 SOP shall be retained for at least one year after the expiry date of the finished product. 12.4 Data may be recorded by electronic data processing systems but Master Formulae and detailed operating procedures relating to the system in use shall also be available in a hard copy to facilitate checking of the accuracy of the records .
  • 24. 13. Labels and other Printed Materials . Labels are necessary for identification of the drugs and their use. The Printing shall be done in bright colours and in a legible manner. The label shall carry all the prescribed details about the product. 13.1 All containers and equipment shall bear appropriate labels. 13.2 Prior to release, all labels for containers shall be examined by the QC Department. 13.3 Records of receipt of all labelling and packaging materials shall be maintained and unused coded and damaged labels and packaging materials shall be destroyed and recorded.
  • 25. 14. Quality Assurance. It is a wide-ranging concept concerning all matters that individually or collectively influence the quality of a product. It shall ensure that: - (a) the pharmaceutical products are designed and developed in a way that takes account of the requirement of GMP ,GLP and GCP. (b) adequate controls on starting materials, intermediate products, and other in-process controls, calibrations, and validations are carried out. (c) products are released after authorized persons have certified.
  • 26. 15. Self inspection and Quality Audit: 15. Self inspection and Quality Audit It is for the assessment of all or part of a system with the specific purpose of improving it. 15.1 The program is designed to detect shortcomings in the implementation of GMP and to recommend the necessary corrective actions. Self-inspections shall be performed routinely and on specific ocasions . The team responsible for self-inspection shall consist of independent, experienced, qualified persons from within or outside the company who can evaluate the implementation of GMP objectively; all recommendations for corrective action shall be implemented. 15.2 The procedure for self-inspection shall be documented indicating self-inspection results; evaluation, conclusions and recommended corrective actions with
  • 27. 16. Quality Control System. Quality control shall be concerned with sampling, specifications, testing, documentation, release procedures . Materials are not released for use, nor products released for sale or supply until their quality has been judged to be satisfactory. 16.1 QC lab should have qualified and experience staff. 16.2 QC lab. may be divided into Chemical, Instrumentation, Microbiological and Biological testing. 16.3 The QC department shall conduct stability studies of the products to ensure and assign their shell life . All records of such studies shall be maintained. 16.4 All instruments shall be calibrated and validated before adopted for routine testing. 16.5 Pharmacopoeia, reference standards, working standards, references spectra, other reference materials and technical books, as required, shall be available in the
  • 28. 17. Specification 17.1 For raw materials and packaging materials. They shall include : a) the designated name and internal code reference; b) reference, if any, to a pharmacopoeial monograph; c) qualitative and quantitative requirements with acceptance limits; d) name and address of manufacturer or supplier and original manufacturer of the material; e) specimen of printed material; f) directions for sampling and testing or reference to procedures ; g) storage conditions; and h) maximum period of storage before re-testing. 17.2 For finished products. Appropriate specifications for finished products shall include: - a) the designated name of the product and the code reference; b) the formula or
  • 29. 18. Master Formula Records . There shall be Master Formula records relating to all manufacturing procedures for each product and batch size. These shall be prepared and endorsed by head of production and quality control. The master Formula shall include : - (a) the name of the product together with product reference code relating to its specifications; (b) the patent or proprietary name of the product along with the generic name, a description of the dosage form, strength, composition of the product and batch size; (c) name, quantity, and reference number of all the starting materials to be used. (d) A statement of the processing location and the principal equipment to be used. (e) detailed stepwise processing instructions and the time taken for each step; (f) the instructions for in-process control with their limits;
  • 30. 19. Packing Records . There shall be authorised packaging instructions for each product, pack size and type . These shall include or have a reference to the following: - (a) name of the product; (b) description of the dosage form, strength and composition; (c) the pack size expressed in terms of the number of doses, weight or volume of the product in the final container; (d) special precautions to be observed, including a careful examination of the area and equipment in order to ascertain the line clearance before the operations begin.
  • 31. 20. Batch Packaging Records . A batch packaging record shall be kept for each batch or part batch processed. It shall be based on the relevant parts of the packaging instructions, and the method of preparation of such records shall be designed to avoid transcription errors. 21. Batch Processing Records. There shall be Batch Processing Record for each product. It shall be based on the relevant parts of the currently approved Master Formula. The method of preparation of such records included in the Master Formula shall be designed to avoid transcription errors.
  • 32. 22. Standard Operating Procedures (SOPs) There shall be written SOP and records for the : receipt of each delivery of raw, primary and printed material. internal labelling, quarantine and storage of starting materials, packaging materials and other materials, as appropriate. for each instrument and equipment. sampling which include the person(s) authorized to take the samples. describing the details of the batch numbering which ensure that each batch of intermediate, bulk or finished product is identified with a specific batch number. testing materials and products at different stages of manufacture, describing the methods and equipment to be used.
  • 33. 23. Reference Samples 23.1 Each lot of every active ingredient, in a quality sufficient to carryout all the tests, except sterility and pyrogens / Bacterial Endotoxin Test, shall be retained for a period of 3 months after the date of expiry of the last batch produced from that active ingredient. 23.2. Samples of finished formulations shall be stored in the same or simulated containers in which the drug has been actually marketed.
  • 34. 24.1 Reprocessing and Recoveries 2. Validation and process validation. Validation studies shall be an essential part of GMP and shall be conducted as per the pre-defined protocols. A written report summarizing recorded results and conclusions shall be prepared, documented and maintained. When any new Master Formula or method of preparation is adopted, steps shall be taken to demonstrate its suitability for routine processing. Significant changes to the manufacturing process, including any changes in equipment or materials shall be validated.
  • 35. 24. Complaints and Adverse Reactions. All complaints there of concerning product quality shall be carefully reviewed and recorded according to written procedures. Each complaint shall be investigated /evaluated by the designated personnel of the company and records of investigation and remedial action taken thereof shall be maintained. Reports of serious adverse drug reactions resulting from the use of a drug shall be forthwith reported to the concerned licensing authority.
  • 36. 25. Site Master File. The licensee shall prepare a succinct document in the form of Site Master File containing specific and factual GMP about the production and/or control of pharmaceutical manufacturing preparations carried out at the licensed premises. It shall contain the following: - General information, Personnel. Premises. Equipment. Sanitation. Documentation. Production. Quality Control. Loan licence manufacture and licensee. Distribution, complaints and product recall. Export of drugs.